Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angioimmunoblastic lymphadenopathy

S J Azevedo, A A Yunis

    American Journal of Hematology
    |November 1, 1985
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Vitamin D3 and chemotherapy-induced alopecia.

    Nutrition (Burbank, Los Angeles County, Calif.)·1996
    Same author

    Familial infantile thrombotic thrombocytopenic purpura.

    Journal of pediatric hematology/oncology·1996
    Same author

    Pretreatment with 1,25(OH)2D3 protects from Cytoxan-induced alopecia without protecting the leukemic cells from Cytoxan.

    The American journal of the medical sciences·1995
    Same author

    Breast-conserving surgery and definitive radiation: a comparison between quadrantectomy and local excision with special focus on local-regional control and cosmesis.

    International journal of radiation oncology, biology, physics·1993
    Same author

    Blood dyscrasias and topical ophthalmic chloramphenicol.

    American journal of ophthalmology·1993
    Same author

    Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3.

    Cancer research·1992
    Same journal

    Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B-ALL.

    American journal of hematology·2026
    Same journal

    Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

    American journal of hematology·2026
    Same journal

    Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.

    American journal of hematology·2026
    Same journal

    Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

    American journal of hematology·2026
    Same journal

    Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

    American journal of hematology·2026
    Same journal

    Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

    American journal of hematology·2026
    See all related articles